Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NXT-10796
- Development stage
- Unknown
- Lead developer
- Inception Sciences
01
Overview
NXT-10796: sourced facts only. name: "Oral administration of NXT-10796 demonstrated tissue specific activation of the EP4 receptor through modulation of immune genes in the colon, without modulation of EP4 driven biomarkers in the plasma compartment." [PMID:37270073]; target: "Oral administration of NXT-10796 demonstrated tissue specific activation of the EP4 receptor through modulation of immune genes in the colon, without modulation of EP4 driven biomarkers in the plasma compartment." [PMID:37270073]; developer: "Inception Sciences Canada Inc., 7150 rue Frederick-Banting, Saint-Laurent, Quebec H4S 2A1, Canada." [PMID:37270073]
02
Targets
PTGER4 (Prostaglandin E2 receptor EP4 subtype)
Beyond the preview
Go deeper on NXT-10796.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NXT-10796.